# Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

> **NCT07486453** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Primary Hypertension

## Interventions

- **DRUG:** Sequence A T-R-T-R
- **DRUG:** Sequence B R-T-R-T

## Key facts

- **NCT ID:** NCT07486453
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-04-25
- **Final completion:** 2026-04-25
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486453, "Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07486453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*